This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through March 4, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $63.42, signifying a -1.93% move from its prior day's close.
Viking (VKTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports first-quarter earnings results.
Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies
by Zacks Equity Research
Data from Eli Lilly's (LLY) SURMOUNT-OSA studies show that treatment with tirzepatide results in a mean AHI reduction of up to 63% in adults with obstructive sleep apnea and obesity.
Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $71.67, indicating a -1.59% shift from the previous trading day.
Zacks Investment Ideas feature highlights: SPDR S&P Biotech ETF, iShares Biotech ETF, Viking Therapeutics and Madrigal Pharmaceuticals
by Zacks Equity Research
SPDR S&P Biotech ETF, iShares Biotech ETF, Viking Therapeutics and Madrigal Pharmaceuticals have been highlighted in this Investment Ideas article.
2 Top Biotech Buyout Candidates
by Andrew Rocco
The resurgence of biotech stocks in recent months marks a promising trend for investors, fueled by a favorable market condition. Strategist Andrew Rocco divulges two biotech stocks with innovative drug pipelines that offer investors the potential to cash in on lucrative buyout opportunities
Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates
by Ekta Bagri
Praxis Precision Medicines, Inc. (PRAX) and Viking Therapeutics, Inc. (VKTX) gain from positive study updates.
Viking (VKTX) Up 17% on Encouraging Oral Obesity Drug Data
by Zacks Equity Research
Data from an early-stage study shows that patients who received Viking's (VKTX) orally-administered obesity drug lost up to 5.3% of their body weight after 28 days.
Zacks Investment Ideas feature highlights: Apple, Alphabet, Eli Lilly, Novo Nordisk and Viking Therapeutics
by Zacks Equity Research
Apple, Alphabet, Eli Lilly, Novo Nordisk and Viking Therapeutics have been highlighted in this Investment Ideas article.
Time to be "Overweight" Viking Therapeutics
by Andrew Rocco
A rising obesity rate and the desire for a quick fix are driving the burgeoning weight loss industry. Stock Strategist Andrew Rocco explains why VKTX stands to benefit the most.
Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
by Zacks Equity Research
Madrigal Pharmaceuticals' (MDGL) Rezdiffra (resmetirom) is the first and only medicine approved by the FDA for the treatment of NASH.
Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals
by Zacks Equity Research
Ionis (IONS) reports positive phase II study results, which show that treatment with ION224 has the potential to improve MASH and prevent its progression to more severe stages.
Novo Nordisk (NVO) Up on Upbeat Data From New Obesity Pill Study
by Zacks Equity Research
Novo Nordisk (NVO) stock rises as it presents encouraging efficacy data on a new investigational oral obesity pill, amycretin, at its Capital Markets Day.
Viking (VKTX) Stock Down on Novo Nordisk's Obesity Pill Data
by Zacks Equity Research
Viking Therapeutics (VKTX) falls as VK2735's placebo-adjusted mean weight loss after 13 weeks of treatment in a phase II study appears similar to Novo Nordisk's amycretin in a phase I study.
Zacks Investment Ideas feature highlights: Meta Platforms, AT&T, BITB, IWM and Viking Therapeutics
by Zacks Equity Research
Meta Platforms, AT&T, BITB, IWM and Viking Therapeutics are part of the Zacks Investment Ideas article.
Company News for Feb 28, 2024
by Zacks Equity Research
Companies In The Article Are: HES, CVX, M,VKTX and UNH
Beyond the "Mag 7": 3 Risk-On Market Forces
by Andrew Rocco
The biggest bear argument over the past year has been the slim leadership in the market, namely concentrated in mega-cap tech stocks like the "Mag 7." However, dig deeper, and you will discover that the market is broadening quickly.
Brian's Big Idea on Healthcare
by Brian Bolan
Big moving drug stocks and the HealthCare Innovators service at Zacks.
Ligand (LGND) Posts Long-Term Outlook, Updates Portfolio Progress
by Zacks Equity Research
Ligand (LGND) aims to generate annual core sales of around $290 million by 2028. It expects revenues from royalties to witness a CAGR of 16% over the next five years.
Akero (AKRO) Slumps 63% on Mixed Results From NASH Study
by Zacks Equity Research
Data from a mid-stage study shows that Akero Therapeutics' (AKRO) lead candidate failed to achieve statistical significance in its primary endpoint of fibrosis improvement in cirrhotic NASH patients.
Madrigal (MDGL) to Raise Capital Via Public Offering of $500M
by Zacks Equity Research
Madrigal (MDGL) is raising funds through a public offering of 1.25 million shares of its common stock to use in commercial activities in the preparation of a potential launch of resmetirom in the United States.
Madrigal (MDGL) Gains on NDA for NASH Therapy Acceptance by FDA
by Zacks Equity Research
Madrigal (MDGL) gains as new drug application for resmeritom to treat nonalcoholic steatohepatitis gets accepted by the FDA in the United States.
Ligand (LGND) Up 4% on Raised '23 EPS, Beats on Q2 Earnings
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) reports second-quarter results as earnings beat the estimates, but sales miss the mark. Management raises the 2023 financial outlook.
Intercept (ICPT) Q2 Earnings Top Estimates, Revenues Up Y/Y
by Zacks Equity Research
Intercept (ICPT) reports a lower net loss and beats on revenues in the second quarter. The company also updates its guidance for its lead drug, Ocaliva.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI